SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

tabelecleucel

ATRA·Atara Biotherapeutics, Inc.
NEUTRAL
Drug Impact Rating8/10
Trial phase
Filed/PDUFA (BLA resubmitted and accepted by FDA)
Time to market
The FDA PDUFA target action date is March 31, 2027, approximately 4.5 months from today. If approved, launch in the US would follow shortly after.
Why 8/10
The PDUFA target action date of March 31, 2027 (approximately 4.5 months away) is the single next binary catalyst for tabelecleucel, the company's lead and near-sole asset. Approval or a third CRL will define Atara's trajectory. Score 8 (not 9-10) because the company does have modest European commercialization revenue and a thin pipeline beyond this indication, but this one drug drives nearly the entire investment thesis.
Actionable Insight NEUTRAL

The next hard catalyst is the FDA PDUFA target action date of March 31, 2027 for the BLA resubmission of tabelecleucel in EBV+ PTLD. Approval would make it the first FDA-approved therapy for this ultra-rare condition and could drive significant upside from the current ~$7.70 share price (analyst mean target $13.67). A third CRL would likely be devastating for the stock given the company's narrow focus on this asset.

Price Chart

Loading chart...

Executive Summary

Tabelecleucel (tab-cel / Ebvallo) is an allogeneic T-cell immunotherapy targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare and life-threatening complication of organ or stem-cell transplants. Developed by Atara Biotherapeutics (NASDAQ: ATRA) in partnership with Pierre Fabre, it is already approved in Europe but has received two Complete Response Letters from the FDA (the most recent on January 9, 2026 triggered a ~66% stock crash). The FDA accepted a third BLA resubmission on October 14, 2026 and set a PDUFA target action date of March 31, 2027. If approved, it would be the first FDA-approved therapy for this ultra-rare indication. The stock trades near $7.70 with an analyst consensus price target of $13.67, reflecting the binary nature of the upcoming FDA decision. The company generated $1.22M in European commercialization revenue in Q3 2026 and faces an active securities class action lawsuit over prior FDA disclosures.

How It Works

Tabelecleucel is an 'off-the-shelf' (allogeneic) T-cell immunotherapy. It uses donor-derived T cells that are specially trained to recognize and kill cells infected with the Epstein-Barr virus (EBV). In transplant patients whose immune systems are suppressed, EBV can trigger a rare and aggressive cancer-like condition called post-transplant lymphoproliferative disease (PTLD). Tabelecleucel delivers ready-made EBV-fighting T cells directly to the patient to control the disease.

Trial Status

The BLA is supported primarily by the single-arm Phase 3 ALLELE trial in EBV+ PTLD patients who have failed rituximab therapy. The FDA previously rejected the application twice, citing concerns about the adequacy of the trial data. The third resubmission includes additional clinical data and manufacturing evidence aligned with feedback from an April 2026 Type A meeting with the FDA. The drug is already approved in Europe under the brand name Ebvallo.

The Two-Sided Case

▲ Bull Case5
Tabelecleucel would be the first FDA-approved treatment for EBV+ PTLD, an ultra-rare and life-threatening complication of organ or stem-cell transplant with no approved US therapy.
The FDA accepted the resubmitted BLA in October 2026 and assigned a PDUFA date of March 31, 2027, signaling the agency found the new data package sufficient for review.
The drug is already approved in Europe (marketed as Ebvallo) and generated $1.22M in Q3 2026 commercialization revenue, providing some real-world commercial validation.
Analyst consensus is bullish (8 Buy/Strong Buy, 2 Hold, 0 Sell) with a mean price target of $13.67, implying ~78% upside from the current ~$7.70 price. Director Brian Cherry bought ~$1M of stock at $9.60/share in September 2026.
UBS and Vanguard both doubled their positions in Q3 2026, signaling institutional confidence in the resubmission.
▼ Bear Case4
Two prior Complete Response Letters (most recently Jan 9, 2026, which triggered a ~66% single-day crash from $17.44 to $5.88) underscore the FDA's shifting and unpredictable stance on the ALLELE trial data.
The FDA has twice deemed the Phase 3 ALLELE trial inadequate to support approval, and the third attempt relies on the same trial with additional supportive data and manufacturing evidence; the risk of a third CRL remains high.
Atara is a net cash-burning company with only $1.22M in quarterly commercialization revenue (from Europe), and its market cap/survival depends almost entirely on this single FDA decision.
An active securities class action lawsuit (filed after the Jan 2026 CRL) adds legal overhang and potential liability.

Upcoming Catalysts

  • PDUFA target action date: March 31, 2027 (FDA decision on BLA resubmission for EBV+ PTLD)
  • Possible FDA Advisory Committee meeting (if scheduled)
  • Resolution of securities class action lawsuit

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Atara Biotherapeutics, Inc. 8-K ATRA ·Originating report

Sources · 8

Hover a chip for the title
1 cancernetwork.com2 morningstar.com3 bioworld.com4 cancernetwork.com5 cancernetwork.com6 quiverquant.com7 tipranks.com8 markets.financialcontent.com